Apixaban vs warfarin in atrial fibrillation ‡
Setting: 1034 centers in 39 countries.
Patients: 18 201 patients (median age 70 y, 65% men, mean CHADS 2 score 2.1) with AF or atrial flutter at enrollment or ≥ 2 episodes of AF or atrial flutter ≥ 2 weeks apart in the 12 months before enrollment, and ≥ 1 of age ≥ 75 years; previous stroke, transient ischemic attack, or systemic embolism; systolic heart failure within 3 months or left ventricular ejection fraction ≤ 40%; diabetes mellitus; and hypertension requiring pharmacologic treatment. Exclusion criteria included AF due to a reversible cause, moderate or severe mitral stenosis, need for anticoagulation other than for AF, stroke within 7 days, need for aspirin at a dose > 165 mg/d or for both aspirin and clopidogrel, and severe renal insufficiency.
Intervention: Apixaban, 5 mg twice daily, plus warfarin placebo (n = 9120), or warfarin, adjusted to achieve a target international normalized ratio (INR) of 2.0 to 3.0, plus apixaban placebo (n = 9081). Apixaban patients received 2.5 mg twice daily if they had ≥ 2 of age ≥ 80 years, body weight ≤ 60 kg, and serum creatinine level ≥ 133 µmol/L (1.5 mg/dL).
Outcomes: Primary efficacy outcome was a composite of stroke or systemic embolism. Primary safety outcome was major bleeding. Secondary outcomes included all-cause mortality and a composite of major bleeding and clinically relevant nonmajor bleeding.
Patient follow-up: 97.9% for vital status (intention-to-treat analysis).
Main results
The main results are in the Table.
Conclusion
In patients with atrial fibrillation, apixaban reduced stroke and systemic embolism compared with warfarin.
*Information provided by author. †See Glossary.
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Commentary
Although warfarin prevents stroke in patients with nonvalvular AF, interactions with food and drugs and genetics necessitate frequent monitoring and dose adjustments, making it difficult for many patients to use warfarin effectively and safely. Hence, alternative oral anticoagulants that are equally efficacious and safe, but more easily administered, have long been sought by clinicians and patients.
The first of such anticoagulants to be tested was a direct thrombin inhibitor; the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY) showed that dabigatran reduced the risk for stroke or systemic embolism by 34%, without increasing bleeding, compared with warfarin (1).
The results of 2 trials assessing factor Xa inhibitors are reported here. The ARISTOTLE trial, which included patients at high risk for stroke (mean CHADS 2 score 2.1), showed that, at 2 years of follow-up, apixaban reduced stroke or systemic embolism (mostly due to a decrease in hemorrhagic stroke), all-cause mortality, and major bleeding, compared with warfarin. The risk for gastrointestinal bleeding, a source of major bleeding in the elderly, was numerically lower in patients treated with apixaban. Interestingly, patients with moderate-to-severe renal impairment were most likely to benefit from the lower risk for bleeding with apixaban.
The ROCKET AF assessed the effect of rivaroxaban in an older population (mean age 73 y vs 70 y) with more comorbid conditions and higher risk for stroke (mean CHADS 2 score 3.5 vs 2.1) than ARISTOTLE. Compared with warfarin, rivaroxaban reduced stroke and systemic embolism but without a reduction in major bleeding, although it did decrease intracranial hemorrhage and fatal bleeding.
All 3 new anticoagulants reduced risk for stroke (mostly hemorrhagic, by preservation of tissue factor VIIa complexes in the brain [2] ) and systemic embolism as well as serious bleeding compared with warfarin; apixaban also reduced rates of major and gastrointestinal bleeding. Patients: 14 264 adults ≥ 18 years of age (median age 73 y, 60% men, mean CHADS 2 score 3.5) who had electrocardiographydocumented nonvalvular AF and a history of stroke; transient ischemic attack; systemic embolism; or ≥ 2 of heart failure or left ventricular ejection fraction ≤ 35%, hypertension, age ≥ 75 years, and diabetes mellitus. Exclusion criteria included AF due to a reversible cause, hemodynamically significant mitral valve stenosis, need for anticoagulation other than for AF, stroke within 14 days, and treatment with aspirin > 100 mg/d.
Intervention:
Rivaroxaban, 20 mg/d or 15 mg/d in patients with creatinine clearance of 30 to 49 mL/min, plus warfarin placebo (n = 7131), or warfarin, adjusted to achieve a target international normalized ratio (INR) of 2.0 to 3.0, plus rivaroxaban placebo (n = 7133).
Outcomes: Primary efficacy outcome was a composite of stroke or systemic embolism. Primary safety outcome was a composite of major or nonmajor clinically relevant bleeding. Secondary efficacy endpoints included a composite of stroke, systemic embolism, cardiovascular death, or myocardial infarction; and individual components of the composite outcomes.
Patient follow-up: 97.8%.
Main results
Conclusion
In patients with nonvalvular atrial fibrillation, rivaroxaban reduced stroke and systemic embolism compared with warfarin. In addition, apixaban reduced mortality compared with warfarin, a trend that was observed with dabigatran (1) and rivaroxaban.
Despite their similarities, there are important differences among the trials of these anticoagulants. Whereas patients and clinicians were not blinded to treatment in the RE-LY trial (1), the ROCKET AF and ARISTOTLE trials were double-blind. Dabigatran and apixaban were given twice daily, wheras rivaroxaban was given only once daily. Patients in the ROCKET AF were older and had more comorbid conditions and higher risk for stroke than those in the RE-LY and ARISTOTLE trials. Finally, the average amount of time in which the INR was in the therapeutic range (assessing the quality of warfarin dosing) was 64% in the RE-LY trial (1) and 62% in the ARISTOTLE trial but only 55% in the ROCKET AF.
Although direct thrombin and factor Xa inhibitors overcome the need for routine blood monitoring and are more effective and safer than warfarin, switching to a newer agent may not be necessary for individual patients in whom INR has been well-controlled with warfarin for years. As well, agents to reverse the effect of the newer anticoagulants are still under development and not routinely available (3). Finally, future data on cost-effectiveness will further influence clinical decision-making. Thus, although newer anticoagulants are attractive alternatives, warfarin may continue to be used worldwide in many patients with AF.
